Clinical trial NCT04724837: Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
Official title: A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate (eGFR) ≥ 20 mL/Min/1.73 m^2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Kidney Disease
Keywords: Zibotentan
Nephrology
Dapagliflozin
Sodium-glucose co-transporter 2
sodium-glucose co-transporter 2 inhibitor
Kidney diseases
Endothelin antagonist
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2021-01-26
Enrollment: 542
Sex: ALL
Minimum age (years): 18
Maximum age (years): 130
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and ≤ 5000 mg/g.

Detailed description: The study will be conducted in approximately 220 sites in North America, South America, Africa, Asia/Pacific, and European countries.

Participants will be randomized to 12 weeks of treatment plus 2 weeks follow-up.

After screening, eligible participants will be stratified by diabetes (diabetic kidney disease \[DKD\] versus non-diabetes mellitus \[non-DM\] CKD) and baseline eGFR (below or equal versus above 45 mL/min/1.73m\^2).

A total of 495 participants will be randomised into this study, including participants randomised under the earlier study design. Four hundred and fifteen (415) participants will be randomised to have 166 participants in zibotentan Dose A/dapagliflozin 10 mg combination arm and dapagliflozin 10 mg monotherapy arm, and 83 participants in the zibotentan Dose B/dapagliflozin 10 mg combination arm.

* Zibotentan Dose A + Dapagliflozin 10 mg once daily.
* Zibotentan Dose B + Dapagliflozin 10 mg once daily.
* Placebo + Dapagliflozin 10 mg once daily

Participants who were previously randomised cannot be re-randomised.

Eligibility criteria: Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

* Diagnosis of Chronic kidney disease (CKD), defined as:

  (a) eGFR chronic kidney disease epidemiology collaboration (CKD-EPI) ≥ 20 mL/min/1.73 m\^2, and (b) UACR ≥ 150 and ≤ 5000 mg albumin/g creatinine, based on a single first morning void spot urine sample at screening.
* No current or prior (within 1 month of screening) medical treatment with an SGLT2i (sodium-glucose co-transporter 2 inhibitor) or any fixed dose combination with SGLT2i.
* If Angiotensin-converting enzyme inhibitors (ACEi) and/or Angiotensin receptor blockers (ARB) and/or mineralocorticoid receptor agonist are prescribed, the dose must be stable ≥ 4 weeks before screening. Participants who have been deemed unable to tolerate ACEi or ARB therapy due to allergy or complications can be enrolled.
* No current or prior treatment within 6 months prior to screening with cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary kidney disease.
* Body mass index ≤ 40 kg/m\^2.
* Male or female of non-childbearing potential.
* Female participants must have a negative pregnancy test at screening, must not be lactating, and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:

  * Postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone and luteinizing hormone levels in the postmenopausal range.
  * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.
* Male participants must be surgically sterile, abstinent, or in conjunction with a female sexual partner, using a highly effective method of contraception for the duration of the study (from the time they sign consent) and for 3 months after the last dose of investigational product to prevent any pregnancies. Male study participants must not donate or bank sperm during this same time period.
* Capable of giving signed informed consent, as described in Appendix A, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* Provision of signed and dated, written ICF prior to any mandatory study-specific procedures, sampling, and analyses.
* Provision of signed and dated written Genetic informed consent prior to collection of samples (optional) for genetic analysis.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

* Minimal change disease, unstable rapidly progressing renal disease, and/or renal disease requiring significant immunosuppression, autosomal dominant or autosomal recessive polycystic kidney disease.
* Participants with New York Heart Association classification functional heart failure (HF) class III or IV.
* Acute coronary syndrome events within 3 months prior to screening.
* Participants with a B-type natriuretic peptide (BNP) ≥ 200 pg/mL or NT-proBNP ≥ 600 pg/mL (BNP ≥ 400 pg/mL or NT-proBNP ≥ 1200 pg/mL, respectively, if associated with atrial fibrillation) measured by local laboratory at screening (Visit 1).
* Participants with unstable HF requiring hospitalisation for optimisation of HF treatment and/or who have not been stable on HF therapy within 6 months prior to screening
* Heart failure due to cardiomyopathies that would primarily require other specific treatment: eg, cardiomyopathy due to pericardial disease, amyloidosis or other infiltrative diseases, cardiomyopathy related to congenital heart disease, primary hypertrophic cardiomyopathy, cardiomyopathy related to toxic or infective conditions (ie, chemotherapy, infective myocarditis, septic cardiomyopathy).
* High output HF (eg, due to hyperthyroidism or Paget's disease).
* Heart failure due to primary cardiac valvular disease/ dysfunction, severe functional mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.
* Participants with uncontrolled diabetes mellitus (HbA1c \> 12%).
* Participants with Type 1 diabetes mellitus.
* Hyponatremia, defined as serum Na+ \< 135 mmol/L at the time of screening (Visit 1).
* Intermittent or persistent second or third degree atrioventricular block after sinus node dysfunction, with clinically significant bradycardia or sinus pause when not treated with pacemaker.
* Prolonged QT interval (QTcF \> 470 ms) on ECG at screening (Visit 1) or randomisation visit (Visit 2), known congenital long QT syndrome or history of QT prolongation associated with other medications.
* History of any life-threatening cardiac dysrhythmia (continuous or paroxysmal or uncontrolled ventricular rate in participants with atrial fibrillation or atrial flutter).
* Cardiac surgery or non-elective percutaneous coronary interventions (PCI/TAVI) (within 3 months) or open chest coronary artery bypass grafting or valvular repair/replacement (within 3 months) prior to screening or is planned to undergo any of these procedures after randomisation.
* Heart transplantation or left ventricular assist device at any time.
* Kidney or any organ transplantation.
* History or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2i (eg, dapagliflozin, canagliflozin, empagliflozin) or drugs with a similar chemical structure to zibotentan.
* Any clinically significant disease or disorder (eg, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major physical impairment), which might put the participant at risk because of participation in the study, or probable alternative primary reason for participant's symptoms in judgment of investigator, including but not limited to:

  * Isolated pulmonary arterial hypertension \[PAP\] (defined as mean PAP ≥ 25 mmHg at rest) or right ventricular failure; in the absence of left-sided HF
  * Anaemia defined as haemoglobin (Hb) level \< 100 g/L or 10 g/dL at screening (Visit 1)
  * Severe chronic obstructive pulmonary disease or other lung disease including but not limited to pulmonary fibrosis requiring chronic oxygen therapy, regular nebuliser use, or oral steroid therapy
* Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within previous 3 months prior to screening.
* Severe hepatic impairment (Child-Pugh class C Hepatic impairment), aspartate transaminase or alanine transaminase \> 2x the upper limit of normal \[ULN\]; or total bilirubin \> 2x ULN at time of screening.
* Participants with newly detected pathological laboratory values or an ongoing disease condition requiring investigation and/or initiation or adjustment of current treatment (in the opinion of the investigator).
* Positive hepatitis C antibody, or hepatitis B virus, surface antigen at screening.
* Positive human immunodeficiency virus (HIV) test.
* Participants treated with strong or moderate CYP3A4 inhibitor or inducer.
* Any condition outside the renal and CV disease area, such as but not limited to malignancy, with a life expectancy of less than 2 years based on investigator's clinical judgment.
* Confirmation of corona virus disease- 2019 (COVID-19) infection:

  * Participant has a positive test result for severe acute respiratory syndrome coronavirus 2 during screening. Participants who are not hospitalised for COVID-19 infections can be re screened 4 weeks after they have recovered.
  * Participant has been previously hospitalised with COVID-19 infection.
* Ejection fraction \< 50% measured by echocardiogram at screening.
* Participation in another clinical study with an investigational product administered in the last 3 months prior to screening.
* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
* Previous randomisation into the present study.
* Plasma donation within 1 month of the visit at the clinic or any blood donation/blood loss \> 500 mL during the 3 months prior to any visit at the clinic.
* Male participant in a sexually active relation with pregnant or breastfeeding partner.
* Participants can decline to participate in the genetic research and may still participate in the study. Exclusion from this optional genetic research may be for any of the exclusion criteria specified for the main study or any of the following:

  * Previous allogeneic bone marrow transplant.
  * Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.

Primary outcomes:
measure: Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12
timeFrame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Secondary outcomes:
measure: Change in UACR From Baseline to Week 12
timeFrame: From baseline (Week 0 [Day 1]) until Week 12
measure: Change in Office Systolic Blood Pressure From Baseline to Week 12
timeFrame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
measure: Change in Office Diastolic Blood Pressure From Baseline to Week 12
timeFrame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
measure: Change in UACR From Baseline to Week 12
timeFrame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
measure: Change in eGFR From Baseline to Week 1, Week 12, and Week 14
timeFrame: From baseline (Week 0 [Day 1]) until Week 1 (Day 8), Week 12 (Day 84), and Week 14 (Day 98)
measure: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
timeFrame: From Screening (Day -28) until Follow-up visit (Day 98), up to 126 days
measure: Change in eGFR From Week 1 to Week 12
timeFrame: From Week 1 (Day 8) to Week 12 (Day 84)
Other outcomes:
Locations:
city: Huntsville
country: United States
facility: Research Site
state: Alabama
city: Beverly Hills
country: United States
facility: Research Site
state: California
city: Downey
country: United States
facility: Research Site
state: California
city: Fountain Valley
country: United States
facility: Research Site
state: California
city: Laguna Hills
country: United States
facility: Research Site
state: California
city: Los Angeles
country: United States
facility: Research Site
state: California
city: Northridge
country: United States
facility: Research Site
state: California
city: Ontario
country: United States
facility: Research Site
state: California
city: S. Gate
country: United States
facility: Research Site
state: California
city: Tarzana
country: United States
facility: Research Site
state: California
city: Vacaville
country: United States
facility: Research Site
state: California
city: Fort Lauderdale
country: United States
facility: Research Site
state: Florida
city: Hialeah
country: United States
facility: Research Site
state: Florida
city: New Port Richey
country: United States
facility: Research Site
state: Florida
city: Orlando
country: United States
facility: Research Site
state: Florida
city: Riverview
country: United States
facility: Research Site
state: Florida
city: Tampa
country: United States
facility: Research Site
state: Florida
city: Augusta
country: United States
facility: Research Site
state: Georgia
city: Fayetteville
country: United States
facility: Research Site
state: Georgia
city: Wichita
country: United States
facility: Research Site
state: Kansas
city: Owensboro
country: United States
facility: Research Site
state: Kentucky
city: Metairie
country: United States
facility: Research Site
state: Louisiana
city: Shreveport
country: United States
facility: Research Site
state: Louisiana
city: Boston
country: United States
facility: Research Site
state: Massachusetts
city: Flint
country: United States
facility: Research Site
state: Michigan
city: Flint
country: United States
facility: Research Site
state: Michigan
city: Lincoln
country: United States
facility: Research Site
state: Nebraska
city: Las Vegas
country: United States
facility: Research Site
state: Nevada
city: Greenville
country: United States
facility: Research Site
state: North Carolina
city: Jacksonville
country: United States
facility: Research Site
state: North Carolina
city: Kinston
country: United States
facility: Research Site
state: North Carolina
city: Morehead City
country: United States
facility: Research Site
state: North Carolina
city: New Bern
country: United States
facility: Research Site
state: North Carolina
city: Wilmington
country: United States
facility: Research Site
state: North Carolina
city: Marion
country: United States
facility: Research Site
state: Ohio
city: Chester
country: United States
facility: Research Site
state: Pennsylvania
city: Memphis
country: United States
facility: Research Site
state: Tennessee
city: Memphis
country: United States
facility: Research Site
state: Tennessee
city: Arlington
country: United States
facility: Research Site
state: Texas
city: Conroe
country: United States
facility: Research Site
state: Texas
city: Corpus Christi
country: United States
facility: Research Site
state: Texas
city: El Paso
country: United States
facility: Research Site
state: Texas
city: Houston
country: United States
facility: Research Site
state: Texas
city: Houston
country: United States
facility: Research Site
state: Texas
city: Odessa
country: United States
facility: Research Site
state: Texas
city: San Antonio
country: United States
facility: Research Site
state: Texas
city: Waxahachie
country: United States
facility: Research Site
state: Texas
city: Forest
country: United States
facility: Research Site
state: Virginia
city: Newport News
country: United States
facility: Research Site
state: Virginia
city: Spokane
country: United States
facility: Research Site
state: Washington
city: Buenos Aires
country: Argentina
facility: Research Site
city: Caba
country: Argentina
facility: Research Site
city: Caba
country: Argentina
facility: Research Site
city: Cordoba
country: Argentina
facility: Research Site
city: Corrientes
country: Argentina
facility: Research Site
city: Junín
country: Argentina
facility: Research Site
city: Mar del Plata
country: Argentina
facility: Research Site
city: Mar del Plata
country: Argentina
facility: Research Site
city: San Luis
country: Argentina
facility: Research Site
city: San Miguel de Tucuman
country: Argentina
facility: Research Site
city: Santa Fe
country: Argentina
facility: Research Site
city: Adelaide
country: Australia
facility: Research Site
city: Birtinya
country: Australia
facility: Research Site
city: Elizabeth Vale
country: Australia
facility: Research Site
city: Gosford
country: Australia
facility: Research Site
city: Westmead
country: Australia
facility: Research Site
city: Botucatu
country: Brazil
facility: Research Site
city: Campinas
country: Brazil
facility: Research Site
city: Curitiba
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Santo Andre
country: Brazil
facility: Research Site
city: Sao Paulo
country: Brazil
facility: Research Site
city: Sao Paulo
country: Brazil
facility: Research Site
city: São José do Rio Preto
country: Brazil
facility: Research Site
city: São Paulo
country: Brazil
facility: Research Site
city: Gabrovo
country: Bulgaria
facility: Research Site
city: Kozloduy
country: Bulgaria
facility: Research Site
city: Montana
country: Bulgaria
facility: Research Site
city: Plovdiv
country: Bulgaria
facility: Research Site
city: Sliven
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Stara Zagora
country: Bulgaria
facility: Research Site
city: St. John's
country: Canada
facility: Research Site
state: Newfoundland and Labrador
city: London
country: Canada
facility: Research Site
state: Ontario
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Waterloo
country: Canada
facility: Research Site
state: Ontario
city: Pula
country: Croatia
facility: Research Site
city: Vinkovci
country: Croatia
facility: Research Site
city: Gentofte
country: Denmark
facility: Research Site
city: Roskilde
country: Denmark
facility: Research Site
city: Århus N
country: Denmark
facility: Research Site
city: Batumi
country: Georgia
facility: Research Site
city: Gori
country: Georgia
facility: Research Site
city: Gurjaani
country: Georgia
facility: Research Site
city: Kutaisi
country: Georgia
facility: Research Site
city: Marneuli
country: Georgia
facility: Research Site
city: Tbilisi
country: Georgia
facility: Research Site
city: Tbilisi
country: Georgia
facility: Research Site
city: Tbilisi
country: Georgia
facility: Research Site
city: Tbilisi
country: Georgia
facility: Research Site
city: Tbilisi
country: Georgia
facility: Research Site
city: Debrecen
country: Hungary
facility: Research Site
city: Hatvan
country: Hungary
facility: Research Site
city: Miskolc
country: Hungary
facility: Research Site
city: Bari
country: Italy
facility: Research Site
city: Genova
country: Italy
facility: Research Site
city: Germaneto
country: Italy
facility: Research Site
city: Napoli
country: Italy
facility: Research Site
city: Napoli
country: Italy
facility: Research Site
city: Napoli
country: Italy
facility: Research Site
city: Pavia
country: Italy
facility: Research Site
city: San Giovanni Rotondo
country: Italy
facility: Research Site
city: Chiba-shi
country: Japan
facility: Research Site
city: Chuo-ku
country: Japan
facility: Research Site
city: Koshigaya-shi
country: Japan
facility: Research Site
city: Nagoya
country: Japan
facility: Research Site
city: Naka
country: Japan
facility: Research Site
city: Osaka-shi
country: Japan
facility: Research Site
city: Osaka-shi
country: Japan
facility: Research Site
city: Osaka-shi
country: Japan
facility: Research Site
city: Takarazuka-shi
country: Japan
facility: Research Site
city: Tsu-shi
country: Japan
facility: Research Site
city: Ueda-shi
country: Japan
facility: Research Site
city: Yao-shi
country: Japan
facility: Research Site
city: Kuala Lumpur
country: Malaysia
facility: Research Site
city: Kuantan
country: Malaysia
facility: Research Site
city: Breda
country: Netherlands
facility: Research Site
city: Dordrecht
country: Netherlands
facility: Research Site
city: Bialystok
country: Poland
facility: Research Site
city: Krakow
country: Poland
facility: Research Site
city: Oświęcim
country: Poland
facility: Research Site
city: Poznań
country: Poland
facility: Research Site
city: Rzeszow
country: Poland
facility: Research Site
city: Rimavska Sobota
country: Slovakia
facility: Research Site
city: Bellville
country: South Africa
facility: Research Site
city: Bloemfontein
country: South Africa
facility: Research Site
city: Durban
country: South Africa
facility: Research Site
city: George
country: South Africa
facility: Research Site
city: Observatory
country: South Africa
facility: Research Site
city: Pretoria
country: South Africa
facility: Research Site
city: Pretoria
country: South Africa
facility: Research Site
city: Somerset West
country: South Africa
facility: Research Site
city: A Coruna
country: Spain
facility: Research Site
city: Barcelona
country: Spain
facility: Research Site
city: Burela
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Majadahonda
country: Spain
facility: Research Site
city: Malaga
country: Spain
facility: Research Site
city: Palma de Mallorca
country: Spain
facility: Research Site
city: Sevilla
country: Spain
facility: Research Site
city: Valencia
country: Spain
facility: Research Site
city: Valencia
country: Spain
facility: Research Site
city: Chernivtsі
country: Ukraine
facility: Research Site
city: Dnipro
country: Ukraine
facility: Research Site
city: Kharkiv
country: Ukraine
facility: Research Site
city: Kyiv
country: Ukraine
facility: Research Site
city: Kyiv
country: Ukraine
facility: Research Site
city: Ternopil
country: Ukraine
facility: Research Site
city: Uzhhorod
country: Ukraine
facility: Research Site
city: Vinnytsia
country: Ukraine
facility: Research Site
city: Zaporizhia
country: Ukraine
facility: Research Site
city: Zhytomyr
country: Ukraine
facility: Research Site
Study officials:
affiliation: Centre for Nephrology Royal Free Campus University College London Rowland Hill Street London NW3 2PF United Kingdom
name: David C Wheeler, MB ChB, MD, FRCP
role: PRINCIPAL_INVESTIGATOR
affiliation: Nephrology Clinical Trials Center Nephrology and Hypertension Vanderbilt University Medical Center Nashville TN United States of America
name: Jamie P. Dwyer, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Smeijer JD, Kohan DE, Webb DJ, Dhaun N, Heerspink HJL. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. Curr Opin Nephrol Hypertens. 2021 Jul 1;30(4):456-465. doi: 10.1097/MNH.0000000000000716.